BR0209443A - Uso de 3-[1-[2-(1-acetil-2,3-di-hidro-1h-indol-3-il) -etil]-1,2,3,6-tetra-hidropiridin-4-il] -6-cloro-1h-indol, qualquer um de seus enanciÈmeros e sais farmaceuticamente aceitáveis do mesmo, e, método para o tratamento de distúrbio de hiperatividade com deficiência de atenção - Google Patents

Uso de 3-[1-[2-(1-acetil-2,3-di-hidro-1h-indol-3-il) -etil]-1,2,3,6-tetra-hidropiridin-4-il] -6-cloro-1h-indol, qualquer um de seus enanciÈmeros e sais farmaceuticamente aceitáveis do mesmo, e, método para o tratamento de distúrbio de hiperatividade com deficiência de atenção

Info

Publication number
BR0209443A
BR0209443A BR0209443-6A BR0209443A BR0209443A BR 0209443 A BR0209443 A BR 0209443A BR 0209443 A BR0209443 A BR 0209443A BR 0209443 A BR0209443 A BR 0209443A
Authority
BR
Brazil
Prior art keywords
indol
ethyl
pharmaceutically acceptable
acceptable salts
indole
Prior art date
Application number
BR0209443-6A
Other languages
English (en)
Inventor
Klaus Peter Hertel
J Rn Arnt
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of BR0209443A publication Critical patent/BR0209443A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Recrystallisation Techniques (AREA)
  • Indole Compounds (AREA)

Abstract

"USO DE 3-[1-[2-(1-ACETIL-2,3-DI-HIDRO-1H-INDOL-3-IL)-ETIL]-1,2,3,6-TE TRA-HIDROPIRIDIN-4-IL]-6-CLORO-1H-INDOL, QUALQUER UM DE SEUS ENANCIÈMEROS E SAIS FARMACEUTICAMENTE ACEITáVEIS DO MESMO, E, MéTODO PARA O TRATAMENTO DE DISTúRBIO DE HIPERATIVIDADE COM DEFICIêNCIA DE ATENçãO". O uso de 3-[1-[2-(1-acetil-2,3-di-hidro-1H-indol-3-il)-etil]-1,2,3,6-tetra-hidropiridi n-4-il]-6-cloro-1H-indol, qualquer um de seus enanciómeros e sais farmaceuticamente aceitáveis do mesmo para a preparação de uma composição farmacêutica para o tratamento de distúrbio de hiperatividade com deficiência de atenção.
BR0209443-6A 2001-05-09 2002-05-07 Uso de 3-[1-[2-(1-acetil-2,3-di-hidro-1h-indol-3-il) -etil]-1,2,3,6-tetra-hidropiridin-4-il] -6-cloro-1h-indol, qualquer um de seus enanciÈmeros e sais farmaceuticamente aceitáveis do mesmo, e, método para o tratamento de distúrbio de hiperatividade com deficiência de atenção BR0209443A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200100732 2001-05-09
PCT/DK2002/000298 WO2002089797A1 (en) 2001-05-09 2002-05-07 Treatment of adhd

Publications (1)

Publication Number Publication Date
BR0209443A true BR0209443A (pt) 2004-08-03

Family

ID=8160484

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209443-6A BR0209443A (pt) 2001-05-09 2002-05-07 Uso de 3-[1-[2-(1-acetil-2,3-di-hidro-1h-indol-3-il) -etil]-1,2,3,6-tetra-hidropiridin-4-il] -6-cloro-1h-indol, qualquer um de seus enanciÈmeros e sais farmaceuticamente aceitáveis do mesmo, e, método para o tratamento de distúrbio de hiperatividade com deficiência de atenção

Country Status (23)

Country Link
US (1) US7294638B2 (pt)
EP (1) EP1387682A1 (pt)
JP (1) JP2004528361A (pt)
KR (1) KR20040007544A (pt)
CN (1) CN1507351A (pt)
AR (1) AR033287A1 (pt)
BG (1) BG108400A (pt)
BR (1) BR0209443A (pt)
CA (1) CA2446652A1 (pt)
CO (1) CO5540378A2 (pt)
CZ (1) CZ20033197A3 (pt)
EA (1) EA200301221A1 (pt)
HR (1) HRP20030852A2 (pt)
HU (1) HUP0400075A2 (pt)
IL (1) IL158413A0 (pt)
IS (1) IS6992A (pt)
MX (1) MXPA03010136A (pt)
NO (1) NO20034972L (pt)
NZ (1) NZ528896A (pt)
PL (1) PL367778A1 (pt)
SK (1) SK15002003A3 (pt)
WO (1) WO2002089797A1 (pt)
ZA (1) ZA200307955B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003236207A1 (en) * 2002-05-31 2003-12-19 H. Lundbeck A/S The hydrochloride of (s)-(+)-3-(1-(2-(1-acetyl-2,3-dihydro-1h-indol-3-yl)ethyl)-1,2,3,6-tetrahydropyridin-4-yl)-6-chloro-1h-indole
EP1812390A2 (en) * 2004-10-22 2007-08-01 Mark Froimowitz Methylphenidate analogs and methods of use thereof
WO2009136410A2 (en) 2008-04-19 2009-11-12 Nisarga Biotech Pvt. Ltd. Herbal composition for reducing add/adhd and method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
ZA9711376B (en) * 1996-12-20 1998-07-21 Lundbeck & Co As H Indole or dihydroindole derivatives
WO2002046156A2 (en) * 2000-12-06 2002-06-13 Sepracor, Inc. 4,4-disubstituted piperidines for use as dopamine, serotonin and norepinephrine ligands

Also Published As

Publication number Publication date
HUP0400075A2 (hu) 2004-04-28
WO2002089797A1 (en) 2002-11-14
WO2002089797A8 (en) 2004-03-25
SK15002003A3 (sk) 2004-05-04
NO20034972D0 (no) 2003-11-07
EA200301221A1 (ru) 2004-04-29
EP1387682A1 (en) 2004-02-11
HRP20030852A2 (en) 2005-06-30
IS6992A (is) 2003-10-13
MXPA03010136A (es) 2004-03-10
US7294638B2 (en) 2007-11-13
NZ528896A (en) 2004-12-24
JP2004528361A (ja) 2004-09-16
US20040152737A1 (en) 2004-08-05
ZA200307955B (en) 2004-10-13
PL367778A1 (en) 2005-03-07
BG108400A (bg) 2004-11-30
CN1507351A (zh) 2004-06-23
CZ20033197A3 (en) 2004-06-16
IL158413A0 (en) 2004-05-12
NO20034972L (no) 2003-11-07
CA2446652A1 (en) 2002-11-14
KR20040007544A (ko) 2004-01-24
CO5540378A2 (es) 2005-07-29
AR033287A1 (es) 2003-12-10

Similar Documents

Publication Publication Date Title
NO20002121L (no) Benzotiazol-protein-tyrosin-kinaseinhibitorer
TR200102969T2 (tr) Siklik protein tirozin kinaz önleyicileri.
DE60101201D1 (de) Verwendung von nikotinergen acetylcholinrezeptor-agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca
ATE498395T1 (de) Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
NZ517758A (en) Pyrazolopyrimidines useful as therapeutic agents
MX2008008405A (es) Metodos para tratar lupus cutaneo usando compuestos de aminoisoindolina.
TW200631578A (en) Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
BRPI0408782A (pt) inibidores cìclicos da proteìna tirosina cinase
DK0658159T3 (da) Aryliden- og heteroaryliden-oxindol-derivater som tyrosinkinaseinhibitorer
MX2021012507A (es) Metodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin- 1-il)metil)bencil)amino)isoindolin-1,3-diona.
WO2006060507A3 (en) Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
DE602004032522D1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
DE602006019754D1 (de) Verfahren und zusammensetzung, die immunomodulatorische verbindungen zur behandlung von mit niedrigen plasmaleptin-spiegeln in zusammenhang stehenden störungen verwenden
YU88103A (sh) Lecenje adhd
MX2010008220A (es) Metodos que usan compuestos inmunomoduladores para modular nivel de cd59.
ATE546452T1 (de) Pyrazolopyrrolderivate als proteinkinaseinhibitoren
HRP20050075A2 (en) Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
BR0209443A (pt) Uso de 3-[1-[2-(1-acetil-2,3-di-hidro-1h-indol-3-il) -etil]-1,2,3,6-tetra-hidropiridin-4-il] -6-cloro-1h-indol, qualquer um de seus enanciÈmeros e sais farmaceuticamente aceitáveis do mesmo, e, método para o tratamento de distúrbio de hiperatividade com deficiência de atenção
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
MXPA05011064A (es) Combinaciones de paroxetina y [1-(r)-(3, 5-bis-trifluorometi l-fenil)-etil] -metilamida del acido 4-(s)- (4-acetil-piperazin -1-il)-2- (r)-(4-fluoro -2-metil- fenil)-piperidin -1-carboxilico para tratamiento de depresion y/o ansiedad.
MXPA04000775A (es) Uso novedoso del 2 -[5-(4-fluorofenil) -3-piridilmetilamino-metil] -cromano y sus sales fisiologicamente aceptables.
DE60119742D1 (de) Methode zur behandlung der hyperaktiven blase
SE0103795D0 (sv) Compounds and method for the treatment of överactive bladder
NO20073547L (no) Nikotinacetykolinreseptorligander
GB9913458D0 (en) The therapeutic use of d-threo-methylphenidate

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A , 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009.